NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.6300
-0.0300 (-4.55%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.6600
Open0.6893
Bid0.6500 x 900
Ask0.0000 x 900
Day's Range0.5900 - 0.6893
52 Week Range0.2300 - 4.0400
Volume330,390
Avg. Volume2,563,292
Market Cap12.942M
Beta (3Y Monthly)7.55
PE Ratio (TTM)N/A
EPS (TTM)-0.5710
Earnings DateNov 12, 2019 - Nov 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • GlobeNewswire

    NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock

    The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions. The preferred stock, the common stock convertible from the preferred stock, the accompanying warrants and the common stock issuable upon exercise of the warrants  will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

  • GlobeNewswire

    NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million. The Company also agreed to issue unregistered warrants to the investors in a concurrent private placement to purchase up to one share of common stock for each share purchased with an exercise price of $1.15 per share. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., (NYSE American: LTS) is acting as exclusive placement agent for the registered direct offering and concurrent private placement.

  • Business Wire

    NovaBay Pharmaceuticals Reports 2019 Second Quarter Financial Results

    Avenova® sales increase 9% and operating expenses decline 47% over the 2019 first quarter

  • Business Wire

    NovaBay Pharmaceuticals Reports 2019 Second Quarter Net Sales of $1.8 Million

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports net sales of $1.8 million for the three months ended June 30, 2019. Avenova sales for the second quarter of 2019 were $1.6 million, a 9% increase from the first quarter of 2019. “The increase in Avenova sales over the prior quarter is particularly impressive given the 67% reduction we made to our salesforce in March as part of a strategic shift to address the trend toward high-deductible health plans,” said Justin Hall, President and CEO.

  • Business Wire

    NovaBay Pharmaceuticals Issues Letter to Stockholders

    The second quarter of 2019 was transformative for NovaBay. NovaBay has made considerable advancements toward our goals of increasing Avenova accessibility and enhancing the patient experience, while maintaining product affordability in an evolving reimbursement environment. To achieve these goals, we have improved the efficiency of both our prescription sales and our buy-and-build channels, and launched a new direct-to-consumer channel on Amazon.com, making prescription-strength Avenova available for the first time without a prescription.

  • Benzinga

    NovaBay Trades Higher After Compliance Plan Accepted By NYSE

    NovaBay Pharmaceuticals (NYSE: NBY) shares are trading higher after the company said its plan of compliance was accepted by the New York Stock Exchange. NYSE notified NovaBay on April 12 and May 16 that it was out of compliance with exchange listing requirements. NYSE has determined NovaBay has made a reasonable demonstration of its ability to make progress toward regaining compliance by October 12, 2020.

  • Business Wire

    NovaBay Pharmaceuticals Plan of Compliance Accepted by NYSE

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that the New York Stock Exchange has accepted the Company’s plan to regain compliance with the NYSE American’s continued listing standards.

  • Business Wire

    NovaBay Pharmaceuticals Raises $2.4 Million in a Private Placement

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces the closing of a private placement of common stock and warrants with accredited investors, raising gross proceeds of $2.4 million. NovaBay also announces an extension of the maturity date of a $1 million loan agreement with Pioneer Pharma (Hong Kong) Company Limited from July 27, 2019 to July 1, 2020. Investors in the private placement purchased 1,371,427 units at a price of $1.75 per unit.

  • Business Wire

    NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFO

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces the appointments of Justin Hall as President and Chief Executive Officer, and Jason Raleigh as Chief Financial Officer. Hall has served as interim President and CEO, and Raleigh as interim CFO since March 2019.

  • MarketWatch

    NovaBay's stock halted for volatility 18 times as it rockets 557%

    NovaBay Pharmaceuticals Inc.'s stock has blasted off to a more-than 6-fold gain in extremely active Monday afternoon trading, after the specialty pharmaceutical company said its Avenova eye-care product is available to buy without a prescription on Amazon.com. The stock's rocket ride has been bumpy for investors, however, as it has been halted for volatility 18 times, between 10:21 a.m. Eastern and 1:37 p.m. The stock was up 557%, to pace all gainers trading on major market indexes. Trading volume topped 38.3 million shares, compared with the full-day average of about 1.2 million shares. NovaBay said Avenova Direct is available on Amazon in the U.S. in a 20 milliliter size for $29.99. The stock reached an intraday high of $3.02, or more than 9 times Friday's closing price of 32 cents, before paring some gains. It is currently on track to close at the highest level since Sept. 24, 2018. The stock has rallied 46% over the past three months, while the S&P 500 has gained 5.5%.

  • MarketWatch

    NovaBay's stock more than triples after Avenova made available on Amazon without prescription

    Shares of NovaBay Pharmaceuticals Inc. more than tripled in very active premarket trade Monday, after the biopharmaceutical company said its Avenova eye-care product is now available without a prescription on Amazon.com through its new direct-to-consumer online channel. Avenova is a lid and lash spray, designed to remove bacteria and debris on and around the eyelid margin. The stock rocketed 262% on volume of 1.1 million shares, to make it the most actively traded ahead of the open. "While prescription Avenova continues to be available through retail pharmacies and direct in-office sales by certain eye care specialists, patients and physicians have asked for greater accessibility to the product," said NovaBay Chief Executive Justin Hall. "In response, we are launching our new U.S. direct-to-consumer channel, which is a significant step in ensuring easy access at an affordable price." The stock had tumbled 59% year to date through Friday, while the S&P 500 has gained 15%.

  • Business Wire

    NovaBay Pharmaceuticals Launches Avenova® Direct on Amazon.com

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that Avenova® Direct is available at affordable pricing and without a prescription on Amazon.com through the Company’s new direct-to-consumer online channel. Avenova, the leading lid and lash spray, is designed for the removal of bacteria and debris on and around the eyelid margin that contribute to bacterial eye infections, which represent approximately 85% of the dry eye market.

  • Business Wire

    NovaBay Pharmaceuticals Receives NYSE American Communication

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that on May 16, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide requiring stockholders’ equity of $2.0 million or more and $4.0 million or more, respectively, if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years. According to the Exchange, this notice does not impact the Company’s ongoing plan to regain compliance with continued listing standards, which requires the Company to regain such compliance by October 12, 2020 or be subject to delisting procedures.

  • Business Wire

    NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • Business Wire

    NovaBay Pharmaceuticals to Hold First Quarter 2019 Conference Call on May 9, 2019

    Management to discuss new partner pharmacy program and expanded access to in-office direct channel

  • Business Wire

    NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will hold a virtual Annual Meeting of Stockholders on Thursday, May 30, 2019 at 5:00 p.m. Pacific time. Registered holders and beneficial stockholders, who register for the meeting in advance, will be able to participate in the meeting, vote and submit questions during the meeting via a live webcast by visiting www.meetingcenter.io/263757134. The Company also notes that on April 12, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Section 1003(a)(iii) of the NYSE American Company Guide requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years.

  • Business Wire

    NovaBay Pharmaceuticals Announces New Partner Pharmacy Program

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company, announces a new pharmacy partnering program in a continued effort to ensure all patients in the U.S. have reliable and affordable access to prescription Avenova®. The company’s pharmacy partners serve patients across the U.S., and together ensure patients in all 50 states have convenient access to Avenova. “Our commitment to a quality patient experience, along with our expanding national presence ensures every patient who wants Avenova can obtain it at the best price,” said Dan Richards, CEO of Meds In Motion Pharmacy, one of Avenova’s channel partners.

  • Business Wire

    NovaBay Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • ACCESSWIRE

    NovaBay Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 28, 2019 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 28, ...

  • Business Wire

    NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy

    Makes board and executive changes and reduces U.S. sales organization to focus only on high-performing, high potential sales territories and specialty pharmacy channel expansion

  • Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for

    NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales and Introduces 2019 Net Sales Guidance

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces 2018 net sales are expected to be $12.6 million to $12.7 million. “During 2018 we launched a number of refinements to our Avenova commercial strategy as we gained experience from our initial approach,” said Jack McGovern, NovaBay Interim CEO and CFO. “Key drivers of our expected growth include engaging specialty pharmacy providers as channel partners, which provides the dual benefit of significantly improving the overall patient experience and supporting higher per-unit revenue,” he added.

  • Business Wire

    NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • Business Wire

    NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report third quarter 2018 financial results after market close on Wednesday, November 14.

  • Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know

    NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.